Supreme Court backs Bayer in Roundup warning case, narrowing lawsuits over pesticide labels

The U.S. Supreme Court ruled 7-2 on June 25 in favor of Bayer in a major Roundup case, a decision that could sharply narrow thousands of lawsuits over pesticide warning labels.

The case, Monsanto v. Durnell, centered on whether federal pesticide law preempts state failure-to-warn claims when the Environmental Protection Agency has not required a cancer warning on the product label.

Bayer acquired Monsanto in 2018 and now owns Roundup, the glyphosate-based weedkiller that has been at the center of years of litigation over allegations that it caused cancer.

John Durnell, a Missouri resident, said prolonged Roundup use caused his non-Hodgkin lymphoma. A Missouri jury previously awarded him $1.25 million.

The ruling

According to the reporting, the court held that state claims seeking a warning conflict with federal labeling rules under the Federal Insecticide, Fungicide and Rodenticide Act, or FIFRA.

That makes the decision a significant preemption ruling. It strengthens a defense Bayer and other pesticide makers have long argued: if the EPA has not required a warning, state courts should not be able to impose one through tort claims.

AP and other outlets reported the ruling was 7-2, with the majority siding with Bayer in a case that had become a test of the balance between federal regulatory authority and state product-liability law.

How the case got here

Durnell’s lawsuit became one of the most closely watched Roundup cases after it went to trial in Missouri. The jury found for him and awarded damages, adding to the long-running pressure on Bayer from Roundup verdicts and settlements.

Bayer then appealed, asking the Supreme Court to resolve the conflict between federal pesticide regulation and state-law warning claims.

The dispute grew out of a broader fight over what Roundup labels should say. Plaintiffs have argued that the product should have carried a cancer warning. Bayer has said the product was reviewed under federal rules and approved without such a warning.

That tension has made Roundup litigation a recurring issue for the company since it bought Monsanto. The case before the Supreme Court was not just about one verdict, but about whether thousands of similar failure-to-warn claims could continue in state courts.

Why it matters

The ruling is expected to affect thousands of pending Roundup-related cases. If lower courts apply it broadly, it could block many claims built around the argument that Bayer should have added a cancer warning even though federal regulators did not require one.

That should reduce Bayer’s litigation exposure and settlement pressure, at least on warning-based claims. It also gives pesticide manufacturers a stronger federal preemption defense in future label disputes.

The case matters beyond Roundup because it may shape how courts handle similar product-liability claims involving pesticides and other federally regulated chemicals.

Reuters- and AP-style reporting indicated that some other legal theories, including product-design claims, may still be pursued in at least some cases. The ruling therefore appears to narrow the litigation rather than end it entirely.

Regulatory background

The case turned in part on the relationship between state tort law and the EPA’s labeling authority under FIFRA. The reporting says the Court treated the federal rules as controlling where the agency has not required the warning plaintiffs want.

The EPA has maintained that glyphosate is not likely to be carcinogenic when used as directed, while the WHO’s cancer agency classified it as probably carcinogenic in 2015.

That split has helped fuel the long-running public and legal debate over Roundup. It also explains why the warning question has remained central in courtroom fights over the product.

What happens next

The immediate next steps are likely to include reactions from Bayer and from plaintiffs’ lawyers, along with lower-court decisions on how quickly the ruling applies to pending cases.

Courts will also have to sort out which claims survive. The reporting suggests warning-based suits face the biggest obstacle, but it remains to be seen how design-defect theories and other arguments will be treated.

Regulatory commentary is another open question. The research packet flags the possibility of statements from the EPA or the White House, though none were confirmed in the initial reporting window.

For Bayer, the ruling is a major legal win after years of costly Roundup litigation. For plaintiffs, it removes one of the most important paths they have used to pursue damages over alleged pesticide-related cancer risks.